PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2022; 43(01): 068-072
DOI: 10.1055/s-0042-1742660
Original Article

Effect of Menopausal Status on Chemotherapy-Induced Peripheral Neuropathy: Single-Institution Retrospective Audit

Akshita Singh
1   Department of Surgical Oncology, Breast Service, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Nita S. Nair
1   Department of Surgical Oncology, Breast Service, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Sudeep Gupta 
2   Statistician, Clinical Research Secretariat Department, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Vani Parmar
1   Department of Surgical Oncology, Breast Service, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Aruna Prabhu
1   Department of Surgical Oncology, Breast Service, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Rohini Hawaldar
3   Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Rajendra A. Badwe
1   Department of Surgical Oncology, Breast Service, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
› Institutsangaben Funding None.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Introduction Paclitaxel can cause peripheral neuropathy in up to 60% of patients. Chemotherapy-induced peripheral neuropathy (CIPN) compromises quality of life and often leads to dose reduction or discontinuation of lifesaving chemotherapy. Preclinical models have suggested the possible neuroprotective effect of progesterone through remyelination and other mechanisms.

Objectives The aim of this study was to evaluate the incidence of CIPN for different menopausal status.

Materials and Methods We evaluated the effect of menopausal status, as a surrogate for circulating progesterone levels, on the risk of developing paclitaxel-induced peripheral neuropathy, in an audit of breast cancer patients. Data on CIPN (by clinical history and examination) and other variables were collected from the case charts of patients who had received paclitaxel-based chemotherapy for breast cancer at our institution.

Results Five hundred and fifty women were treated with either neoadjuvant or adjuvant paclitaxel in this period. Of these, 262 (47.6%) women were premenopausal, 49 (8.9%) were perimenopausal, and 239 (43.5%) were postmenopausal at the time of diagnosis. Forty-five (8.1%) women had pre-existing diabetes mellitus. Two hundred and fifty-six (82.31%) developed chemotherapy-induced amenorrhea (CIA).

CIPN was seen in 32.7% of women who continued to be premenopausal after receiving chemotherapy and 62.3% of postmenopausal women. Thirty-five (77.8%) out of forty-five diabetic women developed CIPN. On a multivariate logistic regression model, pre-existing diabetes mellitus (risk ratio [RR] = 2.64, 95% confidence interval [CI]: 1.26–5.52, p = 0.009), postmenopausal (RR = 2.84, 95% CI = 1.48–5.45, p = 0.002), and CIA status (RR = 2.17, 95% CI = 1.14–4.12, p = 0.018) were significantly associated with the development of CIPN. Number of cycles did not appear to have an impact (p= 0.819).

Conclusions Postmenopausal status was independently associated with higher incidence of CIPN. One of the possible mechanisms could be lower circulating progesterone levels in these patients. A randomized controlled trial (CTRI/2015/11/006381) is ongoing to test this hypothesis.

Keywords

breast cancer - CIPN - progesterone - taxanes


Publikationsverlauf

Artikel online veröffentlicht:
17. Februar 2022

© 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
    CrossrefPubMedGoogle Scholar
  • 2 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
    CrossrefPubMedGoogle Scholar
  • 3 Seretny M, Currie GL, Sena ES. et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 2014; 155 (12) 2461-2470
    CrossrefPubMedGoogle Scholar
  • 4 Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci 2019; 20 (06) 1451
    CrossrefPubMedGoogle Scholar
  • 5 Ibrahim NK, Desai N, Legha S. et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002; 8 (05) 1038-1044
    PubMedGoogle Scholar
  • 6 Smith RE, Brown AM, Mamounas EP. et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 1999; 17 (11) 3403-3411
    CrossrefPubMedGoogle Scholar
  • 7 du Bois A, Lück HJ, Meier W. et al; Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95 (17) 1320-1329
    CrossrefPubMedGoogle Scholar
  • 8 Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 1994; 35 (03) 304-311
    CrossrefPubMedGoogle Scholar
  • 9 Akerley W, Herndon JE, Egorin MJ. et al. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer 2003; 97 (10) 2480-2486
    CrossrefPubMedGoogle Scholar
  • 10 Chaudhry V, Chaudhry M, Crawford TO, Simmons-O'Brien E, Griffin JW. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003; 60 (02) 337-340
    CrossrefPubMedGoogle Scholar
  • 11 Cavaletti G, Cavalletti E, Montaguti P, Oggioni N, De Negri O, Tredici G. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology 1997; 18 (01) 137-145
    PubMedGoogle Scholar
  • 12 Cavaletti G, Cavalletti E, Oggioni N. et al. Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. Neurotoxicology 2000; 21 (03) 389-393
    PubMedGoogle Scholar
  • 13 Peters CM, Jimenez-Andrade JM, Kuskowski MA, Ghilardi JR, Mantyh PW. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res 2007; 1168: 46-59
    CrossrefPubMedGoogle Scholar
  • 14 Hershman DL, Lacchetti C, Dworkin RH. et al; American Society of Clinical Oncology. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014; 32 (18) 1941-1967
    CrossrefPubMedGoogle Scholar
  • 15 Singh M, Su C. Progesterone and neuroprotection. Horm Behav 2013; 63 (02) 284-290
    CrossrefPubMedGoogle Scholar
  • 16 Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008; 13 (01) 27-46
    CrossrefPubMedGoogle Scholar
  • 17 Molassiotis A, Cheng HL, Lopez V. et al. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 2019; 19 (01) 132
    CrossrefPubMedGoogle Scholar
  • 18 Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006; 24 (10) 1633-1642
    CrossrefPubMedGoogle Scholar
  • 19 Winer EP, Berry DA, Woolf S. et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 2004; 22 (11) 2061-2068
    CrossrefPubMedGoogle Scholar
  • 20 Seidman AD, Berry DA, Woolf S. et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (s) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 2004; 22 (Suppl. 14) 6s [Abstr. 512]
    Google Scholar
  • 21 Sparano JA, Wang M, Martino S. et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358 (16) 1663-1671
    CrossrefPubMedGoogle Scholar
  • 22 Starobova H, Vetter I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci 2017; 10: 174
    CrossrefPubMedGoogle Scholar
  • 23 Prior JC. Progesterone for symptomatic perimenopause treatment - progesterone politics, physiology and potential for perimenopause. Facts Views Vis ObGyn 2011; 3 (02) 109-120
    PubMedGoogle Scholar
  • 24 Dorsey SG, Kleckner IR, Barton D. et al. The National Cancer Institute Clinical Trials planning meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy. J Natl Cancer Inst 2019; 111 (06) 531-537
    CrossrefPubMedGoogle Scholar